Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?

Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?

Alessio Amatu, Katia Bencardino, Andrea Sartore-Bianchi, Salvatore Siena

Department of Oncology, Ospedale Niguarda Ca’ Granda, Milano, Italy

Corresponding to: Salvatore Siena. Director of the Division of Oncology at Ospedale Niguarda Ca' Granda, Milano, Italy. Email:

Submitted Dec 11, 2012. Accepted for publication Jan 15, 2013.

doi: 10.3978/j.issn.2305-5839.2013.01.03

A recent report in The New England Journal of Medicine by Liao and colleagues highlights the benefit of aspirin use in a molecular defined subgroup of patients affected by metastatic colorectal cancer (CRC). Authors concluded that it is very likely that the regular use of aspirin after CRC diagnosis is associated with longer survival among patients with mutated-PIK3CA tumors. In contrast, aspirin has no effect on cancer-specific survival in patients with wild-type PIK3CA CRC (1). The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays an important role in carcinogenesis of CRC. Activating mutations in PIK3CA occur in two “hotspots” located in exon 9 (E542K, E545K) and exon 20 (H1047R) in approximately 15% of CRCs (2). PIK3CA encodes for a lipid kinase that regulates signaling pathways downstream of the Epidermal Growth Factor Receptor (EGFR), and its mutations hamper sensitivity to the anti-EGFR monoclonal antibodies cetuximab or panitumumab registered for metastatic CRC treatment (3,4). Activation of PI3K enhances PTGS2 (prostaglandin-endoperoxide synthase 2, also known as cyclooxygenase-2) activity and prostaglandin E2 synthesis, inhibiting apoptosis of CRC cells. The long standing knowledge of the inhibitory effect of aspirin on PTGS2 may therefore suppress cancer-cell growth and induce apoptosis by blocking the PI3K pathway (1).

Several studies demonstrated that aspirin reduces the incidence of colon polyps, and its preventive effect is detectable even when given at low doses (75 mg daily). After CRC diagnosis, aspirin use reduces recurrence of adenomas (relative risk 0.65 vs. placebo) (5). Recently, a randomized trial in patients affected by Lynch syndrome showed that two years of aspirin 600 mg/die improved CRC-specific outcome (HR 0.63 for CRC incidence) (6). The observation that aspirin reduces the formation of colonic polyps provides the rationale for the use of this drug in the cancer prevention setting. Among participants in a large study of cardiovascular prevention, after long-term follow-up, any dose of daily aspirin displayed cancer preventive effect by lowering by 24% the risk of CRC at 10 years (7). In a pooled analysis of 35,535 patients from 6 randomized trials, aspirin use reduced the risk of developing metastatic CRC and the risk of death from CRC, and this effect was maintained with low aspirin dose (8). However, use of aspirin for primary CRC prevention faces an increased risk of bleeding (9), so a selection of patients who are likely to benefit from this drug is warranted. On the other hand, in the secondary prevention of CRC, Chan and colleagues reported that, after surgical removal of primary tumor, aspirin use reduces the risk of CRC overexpressing COX-2 among patients from two large cohorts (Nurses’ Health Study and Health Professionals Follow-up Study, started in 1976 and 1986, respectively) (10). These results were confirmed in a subsequent analysis of the same cohorts with a 29% CRC mortality risk reduction in the same subgroup of patients whose cancers over-express the enzyme COX-2 (11).

In their recent pivotal study, Liao et al. provided clinical hints for a bridging between molecular bases of CRC progression and pharmacogenomic of aspirin. In particular, they identified a subgroup of patients in whom the mutation of PIK3CA appears to be associated with reduced risk of mortality from CRC. This is the first study demonstrating the association between a specific genetic alteration which is relevant for cancer progression and a reduction in CRC mortality with the use of aspirin. Authors reported indeed a remarkable improvement in CRC-specific mortality and overall survival in a small subgroup of patients (mutated PIK3CA who used aspirin regularly after CRC diagnosis vs. non-users), with a multivariate HR for CRC death of 0.18 (95% CI: 0.06-0.61, P<0.001) and 0.54 (95% CI: 0.31-0.94, P=0.01) for death from any cause. Conversely, tumors with wild-type PIK3CA did not benefit from aspirin use.

Although the hypothesized mechanism of action and data shown are compelling, caution is needed prior considering these results as practice-changing. Firstly, as acknowledged by authors, the statistical sample is limited (the patients with tumor harboring PIK3CA mutations who received aspirin were 62), and the use of multiple statistical tests on the same sample may increase the probability of making observations due to chance. Secondly, interpretation of results is hampered by the lack of detailed follow-up data including subsequent cancer treatments (i.e., adjuvant chemotherapy) which could impact on survival. Thirdly, it cannot be excluded that the use of self-prescribed aspirin, which was reported in many cases by patients for analgesic purposes, may have been associated with wider use of diagnostic investigations and, at least in symptomatic patients, with an anticipation in the detection of relapse, thus leading to an overall better CRC-related outcome.

In conclusion, the study of Liao et al. is providing compelling evidence toward a rationale use of aspirin in molecularly defined subgroup of CRC, but requires validation in independent cohorts of patients. Such studies should have mortality from CRC as primary endpoint and specific follow-up including cancer treatments. In Asia, the randomized ASCOLT trial (12) is undergoing to evaluate the efficacy of aspirin 200 mg daily for stage III and high-risk stage II CRC. It would be of great interest to assess whether the predictive role of PIK3CA mutation will be confirmed in this cohort of patients.


Authors supported by research grants Terapia Molecolare Tumori from Oncologia Ca’ Granda Onlus (OCGO) Fondazione and AIRC 5 x 1000 from Associazione Italiana Ricerca Cancro.

Disclosure: The authors declare no conflict of interest.


  1. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606. [PubMed]
  2. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. [PubMed]
  3. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-7. [PubMed]
  4. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62. [PubMed]
  5. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. [PubMed]
  6. Mathers JC, Movahedi M, Macrae F, et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol 2012;13:1242-9. [PubMed]
  7. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50. [PubMed]
  8. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602-12. [PubMed]
  9. Berger JS, Lala A, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 2011;162:115-24.e2.
  10. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42. [PubMed]
  11. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58. [PubMed]
  12. Ali R, Toh HC, Chia WK, et al. The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. Trials 2011;12:261. [PubMed]
Cite this article as: Amatu A, Bencardino K, Sartore-Bianchi A, Siena S. Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy? Ann Transl Med 2013;1(2):12. doi: 10.3978/j.issn.2305-5839.2013.01.03


  • There are currently no refbacks.